Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APOLLO: Olaparib in Resected Pancreatic Cancer with BRCA/PALB2 Mutation
NCT04858334Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- Jun 2021
- Primary completion
- Oct 2027
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of olaparib in pancreatic cancer (PC), sponsored by National Cancer Institute. Started Jun 2021; status: recruiting.
02
Drugs
olaparib
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT04858334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04858334.